Editas Medicine ( (EDIT) ) has issued an update.
Editas Medicine, Inc. struck a deal on October 3, 2024, with a subsidiary of DRI Healthcare Trust, selling future license fees and payments from Vertex Pharmaceuticals for $57 million. This agreement involves Vertex’s use of Editas’ Cas9 gene-editing technology for treatments of sickle cell disease and beta thalassemia. The Purchaser is entitled to a portion of these fees, ranging from $5 to $40 million annually, including a percentage of a potential $50 million payment, minus obligations to Editas’ licensors. The agreement is detailed with customary terms and conditions, including indemnity provisions, with the potential for Editas to incur liquidated damages or termination fees under certain conditions.
See more data about EDIT stock on TipRanks’ Stock Analysis page.
